Atrium Therapeutics, Inc. (RNA)
Nasdaq: RNA · Pharmaceutical Preparations · filing with the SEC since 2025
Who runs Atrium Therapeutics, Inc.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Gallagher Kathleen P.
Chief Executive Officer and President. First filing Feb 2026, latest Sep 22, 2026, 0 filings in all.
Officers reporting now
6
of 11 people with a filing in the last fifteen months
Directors reporting now
5
11 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Executive Officer and President | Feb 2026 | Sep 22, 2026 | none |
| Winslow Brendan R. | Chief Financial Officer | Feb 2026 | Sep 22, 2026 | none |
| Hoyos Rocio Martin | Chief Strategy Officer | Feb 2026 | Sep 22, 2026 | none |
| Hughes Steven George | Chief Medical Officer | Feb 2026 | Sep 22, 2026 | none |
| Kenney Stephanie | Chief Corporate Affairs Officer | Feb 2026 | Sep 22, 2026 | none |
| Younis Husam | Chief Scientific Officer | Feb 2026 | Sep 22, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Boyce Sarah | director | Feb 2026 | Sep 22, 2026 | none |
| Flanagan W. Michael | director | Feb 2026 | Sep 22, 2026 | none |
| Boess Carsten | director | Feb 2026 | Mar 2, 2026 | none |
| Skerjanec Simona | director | Feb 2026 | Mar 2, 2026 | none |
| Wilson Troy Edward | director | Feb 2026 | Mar 2, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.